EGFR and non-small cell lung carcinoma: For example, in 206 patients with stage IIIB/IV EGFRm NSCLC who had oligo‐PD during the first‐line EGFR‐TKI therapy, continuation of TKI with addition of LAT demonstrates a PFS1 of 10.7 months, PFS2 of 18.3 months, 1‐, 2‐, and 3‐year survival rates of 94.1%, 78.9%, and 54.7%, respectively.